[Importance of analyzing studies of SPECT diagnostic tests in movement disorders].
作者信息
Campillo-Soto A, Lirón-Ruiz R, Martín-Lorenzo J G, del Río-Medel L, Aguayo-Albasini J L
出版信息
Rev Esp Med Nucl. 2009 Sep-Oct;28(5):267. doi: 10.1016/j.remn.2009.05.004. Epub 2009 Jul 28.
PMID:19922848
Abstract
摘要
相似文献
1
[Importance of analyzing studies of SPECT diagnostic tests in movement disorders].
Rev Esp Med Nucl. 2009 Sep-Oct;28(5):267. doi: 10.1016/j.remn.2009.05.004. Epub 2009 Jul 28.
2
[Negative predictive value of SPECT with I123 ioflupane in movement disorders (reply)].
Rev Esp Med Nucl. 2009 Sep-Oct;28(5):267-8. doi: 10.1016/j.remn.2009.05.005. Epub 2009 Jul 28.
3
[Clinical applications of single photon emission tomography in neuromedicine. 1. Neuro-oncology, epilepsy, movement disorders, cerebrovascular disease].
Nuklearmedizin. 2000 Nov;39(7):180-95.
4
[Negative predictive value of (123)I Ioflupane SPECT in movement disorders].
Rev Esp Med Nucl. 2009 Jan-Feb;28(1):2-5.
5
Supplement neuroimaging movement disorders.
Mov Disord. 2009;24 Suppl 2:S655. doi: 10.1002/mds.22770.
6
FP-CIT SPECT evaluation: time to go beyond visual assessment!
Eur J Nucl Med Mol Imaging. 2012 Apr;39(4):727-8. doi: 10.1007/s00259-011-2042-3. Epub 2012 Jan 11.
7
Molecular imaging (SPECT and PET) in the evaluation of patients with movement disorders.
Nucl Med Rev Cent East Eur. 2006;9(2):147-53.
8
Is the time ripe to adopt semiquantitative analysis of SPECT evaluation in movement disorders as a standard?
Eur J Nucl Med Mol Imaging. 2011 Mar;38(3):596-7. doi: 10.1007/s00259-010-1709-5. Epub 2011 Jan 6.
9
[Neuroimaging in movement disorders].
Rev Esp Med Nucl. 2005 Jul-Aug;24(4):221-3. doi: 10.1157/13076639.
10
[Experience with 123I-Iodobenzamide in the differential diagnosis of Parkinson's disease and Parkinson-plus disease].
Rev Esp Med Nucl. 2010 Mar-Apr;29(2):57-62. doi: 10.1016/j.remn.2009.12.008. Epub 2010 Feb 4.
Zotero 插件